A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

PHASE2UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2011

Conditions

Melanoma

Interventions

BIOLOGICAL

HyperAcute vaccine

1.8 mL weekly

DRUG

Pegylated Interferon-Alpha 2b

6.0 mcg/kg weekly

Trial Locations (1)

Ochsner Health System, New Orleans